(Q43856820)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Stanisław J Chrapusta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

P Grieb

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

J Kamienowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

M Janisz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

P Kuśnierczyk

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

G Hoser

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 December 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Hematology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

421-427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf02982086

6 December 2019

exact match

0 references

cites work

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02982086

Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02982086

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02982086

Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas

21 January 2018

1 reference

12 December 2020

Cladribine: a review of its use in multiple sclerosis

1 reference

12 December 2020

Marrow suppression produced by repeated doses of cladribine

1 reference

12 December 2020

Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone

1 reference

12 December 2020

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

1 reference

12 December 2020

Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report

1 reference

12 December 2020

Infectious complications after 2-chlorodeoxyadenosine therapy.

1 reference

12 December 2020

Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy

1 reference

12 December 2020

Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia

1 reference

12 December 2020

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

1 reference

12 December 2020

Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis

1 reference

12 December 2020

Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia

1 reference

12 December 2020

Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

1 reference

12 December 2020

The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status.

1 reference

12 December 2020

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

12 December 2020

Cladribine treatment of multiple sclerosis

1 reference

12 December 2020

Effect of deoxycytidine on 2-chloro-deoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells

1 reference

12 December 2020

Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients

1 reference

12 December 2020

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

1 reference

12 December 2020

Infectious and immunosuppressive complications of purine analog therapy.

1 reference

12 December 2020

A role for natural killer cells in the immunopathogenesis of multiple sclerosis.

1 reference

12 December 2020

Cladribine (2-chlorodeoxyadenosine)

1 reference

12 December 2020

Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients

1 reference

12 December 2020

The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial

1 reference

12 December 2020

Candidate autoantigens in multiple sclerosis

1 reference

12 December 2020

First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

The immune profile of multiple sclerosis: T-lymphocyte effects predominate over all other factors in cyclophosphamide-treated patients.

1 reference

12 December 2020

2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia

1 reference

12 December 2020

T cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine.

1 reference

12 December 2020

Cladribine (2-chloro-deoxyadenosine, CDA): an inhibitor of human B and T cell activation in vitro

1 reference

12 December 2020

Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy

1 reference

12 December 2020

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications

1 reference

12 December 2020

The clinical pharmacokinetics of cladribine

1 reference

12 December 2020

Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02982086

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11794698%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference